Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer
Brief Summary: This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram \[mg/kg\] intravenously \[IV\] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: S-1 + irinotecan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Intervention Type: DRUG; Name: S-1 + irinotecan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): B
B: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
C: Arm Label: Arm A (ECF + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: ECF | Arm Label: Arm B (IC + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: IC | Arm Label: ARM C (FOLFOX + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: FOLFOX | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): ARM C (FOLFOX + cetuximab), Arm A (ECF + cetuximab), Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: ECF; Assigned to Arm(s): Arm A (ECF + cetuximab) | Intervention Type: DRUG; Name: IC; Assigned to Arm(s): Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: FOLFOX; Assigned to Arm(s): ARM C (FOLFOX + cetuximab)
D: Arm Label: Pertuzumab + Trastuzumab + Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Drug: Capecitabine, Drug: Cisplatin, Drug: Pertuzumab, Drug: Trastuzumab | Arm Label: Placebo + Trastuzumab + Chemotherapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: Trastuzumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Pertuzumab + Trastuzumab + Chemotherapy, Placebo + Trastuzumab + Chemotherapy | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Pertuzumab + Trastuzumab + Chemotherapy, Placebo + Trastuzumab + Chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pertuzumab + Trastuzumab + Chemotherapy, Placebo + Trastuzumab + Chemotherapy | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Chemotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Chemotherapy | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Chemotherapy, Placebo + Trastuzumab + Chemotherapy

Answer: D